Description:

Technoview®Arixtra® calibratorset isasetofplasma-derivedcalibration sampleswithArixtra®*concentrations rangingfrom~0-2µg/ml. Thesetcanbeusedfor establishingastandardcurveinresearchmeasurementsofArixtra®. Itisoptimizedforusewithanti-Xachromogenicassaysand isfrequentlyusedinconjunctionwiththe Technoview®Arixtra® lowandhighcontrolsinthe Technochrom®anti-Xachromogenicassay.

*Fondaparinuxsodium istheactivesubstanceinArixtra®.

Advantages:

• Allowsforestablishmentofcalibrationcurvecoveringarangeof0-2 µg/ml
• Optimizedforusewithanti-Xa(withoutexogeneousantithrombin) research assays

CalibratorSetComposition:

5x1mlvialswitharangeofArixtra® concentrations:

• Cal1:0µg/ml
• Cal2:0.5µg/ml
• Cal3:1µg/ml
• Cal4:1.5µg/ml
• Cal5:2µg/ml

Calibratorsare lyophilizedandpreparedfrompooledhumancitratedplasmasupplementedwithdifferent concentrationsofArixtra®.TheplasmacontainsstABIlizersbutnobactericideadditives.ItiscalibratedagainsttheInternationalStandard preparation01/608.

Background:

Arixtra®(fondaparinuxsodium)InjectionisafactorXa(FXa)inhibitordrug.As asyntheticpentasaccharide,itischemicallysimilartolowmolecularweightheparin(LMWH),thoughitisselectiveforFXa.Morespecifically,itshighaffinityantithrombin(AT)binding allowsfor indirectinhibitionofFXa. Useofthisdrugsubstantiallylowerstheriskfor heparin-inducedthrombocytopenia(HIT)andithasnotbeenshownto reactwithHITantibodies.Itisprescribedbyahealthcareproviderandcanbeusedfor:

• prophylaxis ofvenousthromboembolism(VTE)aftermajororthopedicoraBDominalsurgery;or
• treatmentofacuteVTEwhenadmiNISTeredinconjunctionwithwarfarini.e.usedshort-termuntilthewarfarinbloodtestisinthetargetrange.

Inmostcases,Arixtra®doesnotrequireroutinemonitoring.However,itcanbemeasuredusingananti-Xaassaywithappropriatecalibrators(fondaparinuxsodium).Theactivityoffondaparinuxsodiumisexpressedinmgandcannotbecomparedtotheactivitiesofheparinor LMWH.NotethatthiscalibratorsetisforresearchuseonlyintheUSandCanada.